Search

Your search keyword '"Geese, William J"' showing total 136 results
Start Over Author "Geese, William J"
136 results on '"Geese, William J"'

1. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab

Author

Alban, Tyler J., Riaz, Nadeem, Parthasarathy, Prerana, Makarov, Vladimir, Kendall, Sviatoslav, Yoo, Seong-Keun, Shah, Rachna, Weinhold, Nils, Srivastava, Raghvendra, Ma, Xiaoxiao, Krishna, Chirag, Mok, Juk Yee, van Esch, Wim J. E., Garon, Edward, Akerley, Wallace, Creelan, Benjamin, Aanur, Nivedita, Chowell, Diego, Geese, William J., Rizvi, Naiyer A., and Chan, Timothy A.

Published
2024
Full Text
View/download PDF

2. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer

Author

Mason, Mike, Lapuente-Santana, Óscar, Halkola, Anni S., Wang, Wenyu, Mall, Raghvendra, Xiao, Xu, Kaufman, Jacob, Fu, Jingxin, Pfeil, Jacob, Banerjee, Jineta, Chung, Verena, Chang, Han, Chasalow, Scott D., Lin, Hung Ying, Chai, Rongrong, Yu, Thomas, Finotello, Francesca, Mirtti, Tuomas, Mäyränpää, Mikko I., Bao, Jie, Verschuren, Emmy W., Ahmed, Eiman I., Ceccarelli, Michele, Miller, Lance D., Monaco, Gianni, Hendrickx, Wouter R. L., Sherif, Shimaa, Yang, Lin, Tang, Ming, Gu, Shengqing Stan, Zhang, Wubing, Zhang, Yi, Zeng, Zexian, Das Sahu, Avinash, Liu, Yang, Yang, Wenxian, Bedognetti, Davide, Tang, Jing, Eduati, Federica, Laajala, Teemu D., Geese, William J., Guinney, Justin, Szustakowski, Joseph D., Vincent, Benjamin G., and Carbone, David P.

Published
2024
Full Text
View/download PDF

6. 972 Platinum-based chemotherapy reverses human MDSC phenotype and suppressive activity on CD8+ T cells

Author

Ding, Yueyun, primary, Schrand, Ailem, additional, DeBettencourt, Joe, additional, Lako, Ana, additional, Rai, Sharmila Chamling, additional, Tauras, Christine, additional, Bleicher, Zoe, additional, Consedine, Timothy, additional, George, Sangeeth, additional, Balli, David, additional, Simpson, Tyler, additional, Geese, William J, additional, Bhatt, Rupal, additional, Chen, Benjamin, additional, and Ramirez-Alejo, Noe, additional

Published
2023
Full Text
View/download PDF

7. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Author

Hellmann, Matthew D, Rizvi, Naiyer A, Goldman, Jonathan W, Gettinger, Scott N, Borghaei, Hossein, Brahmer, Julie R, Ready, Neal E, Gerber, David E, Chow, Laura Q, Juergens, Rosalyn A, Shepherd, Frances A, Laurie, Scott A, Geese, William J, Agrawal, Shruti, Young, Tina C, Li, Xuemei, and Antonia, Scott J

Published
2017
Full Text
View/download PDF

8. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

Author

König, Katharina, Peifer, Martin, Fassunke, Jana, Ihle, Michaela A., Künstlinger, Helen, Heydt, Carina, Stamm, Katrin, Ueckeroth, Frank, Vollbrecht, Claudia, Bos, Marc, Gardizi, Masyar, Scheffler, Matthias, Nogova, Lucia, Leenders, Frauke, Albus, Kerstin, Meder, Lydia, Becker, Kerstin, Florin, Alexandra, Rommerscheidt-Fuss, Ursula, Altmüller, Janine, Kloth, Michael, Nürnberg, Peter, Henkel, Thomas, Bikár, Sven-Ernö, Sos, Martin L., Geese, William J., Strauss, Lewis, Ko, Yon-Dschun, Gerigk, Ulrich, Odenthal, Margarete, Zander, Thomas, Wolf, Jürgen, Merkelbach-Bruse, Sabine, Buettner, Reinhard, and Heukamp, Lukas C.

Published
2015
Full Text
View/download PDF

13. A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer

Author

Mason, Mike, primary, Lapuente-Santana, Óscar, additional, Halkola, Anni S., additional, Wang, Wenyu, additional, Mall, Raghvendra, additional, Xiao, Xu, additional, Kaufman, Jacob, additional, Fu, Jingxin, additional, Pfeil, Jacob, additional, Banerjee, Jineta, additional, Chung, Verena, additional, Chang, Han, additional, Chasalow, Scott D., additional, Lin, Hung Ying, additional, Chai, Rongrong, additional, Yu, Thomas, additional, Finotello, Francesca, additional, Mirtti, Tuomas, additional, Mäyränpää, Mikko I., additional, Bao, Jie, additional, Verschuren, Emmy W., additional, Ahmed, Eiman I., additional, Ceccarelli, Michele, additional, Miller, Lance D., additional, Monaco, Gianni, additional, Hendrickx, Wouter R.L., additional, Sherif, Shimaa, additional, Yang, Lin, additional, Tang, Ming, additional, Gu, Shengqing Stan, additional, Zhang, Wubing, additional, Zhang, Yi, additional, Zeng, Zexian, additional, Sahu, Avinash Das, additional, Liu, Yang, additional, Yang, Wenxian, additional, Bedognetti, Davide, additional, Tang, Jing, additional, Eduati, Federica, additional, Laajala, Teemu D., additional, Geese, William J., additional, Guinney, Justin, additional, Szustakowski, Joseph D., additional, Carbone, David P., additional, and Vincent, Benjamin G., additional

Published
2022
Full Text
View/download PDF

15. Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design

Author

Khushalani, Nikhil I, primary, Diab, Adi, additional, Ascierto, Paolo A, additional, Larkin, James, additional, Sandhu, Shahneen, additional, Sznol, Mario, additional, Koon, Henry B, additional, Jarkowski, Anthony, additional, Zhou, Ming, additional, Statkevich, Paul, additional, Geese, William J, additional, and Long, Georgina V, additional

Published
2020
Full Text
View/download PDF

18. Nivolumab (N) + Low-Dose Ipilimumab (I) vs Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment (tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Checkmate 227 Part 1 Final Analysis

Author

Reck, Martin, Peters, Solange, Ramalingam, Suresh S., Paz-Ares, Luis G., Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang We, Alexandru, Aurelia, Lupinacci, Lorena, de la Mora Jitnenez, Emmanuel, Sakai, Hiroshi, Albert, István, Vergnenegre, Alain, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Ken, Geese, William J., Bhagavatheeswaran, Prabhu, Nattan, Faith E., Hellmann, Matthew D., Reck, Martin, Peters, Solange, Ramalingam, Suresh S., Paz-Ares, Luis G., Bernabe Caro, Reyes, Zurawski, Bogdan, Kim, Sang We, Alexandru, Aurelia, Lupinacci, Lorena, de la Mora Jitnenez, Emmanuel, Sakai, Hiroshi, Albert, István, Vergnenegre, Alain, Borghaei, Hossein, Brahmer, Julie, O'Byrne, Ken, Geese, William J., Bhagavatheeswaran, Prabhu, Nattan, Faith E., and Hellmann, Matthew D.

Abstract

Background Part 1 of CheckMate 227 (NCT02477826), a phase III study in 1L NSCLC, has dual primary endpoints. The primary endpoint of progression-free survival (PFS) with NIVO + IPI vs chemo in patients (pts) with tumor mutational burden ≥ 10 mut/Mb was met, as reported previously. Here we present the primary endpoint of overall survival (OS) for NIVO + IPI vs chemo in pts with tumor PD-L1 expression ≥ 1%. MethodsPts were chemo-naive, with stage IV or recurrent NSCLC without EGFR or known ALK alterations, ECOG PS 0–1. Pts with PD-L1 ≥1% (n = 1189) were randomized 1:1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W, NIVO 240 mg Q2W, or histology-based chemo; pts with PD-L1 < 1% (n = 550) were randomized 1:1:1 to NIVO 3 mg/kg Q2W + IPI 1 mg/kg Q6W, NIVO 360 mg Q3W + chemo, or chemo. Pts were stratified by histology in both populations. Pts were treated until disease progression, unacceptable toxicity, or for 2 y of immunotherapy. Results Baseline characteristics were balanced across tx arms. Minimum follow-up for the primary endpoint was 29.3 mo. For pts with PD-L1 ≥ 1%, OS was significantly longer with NIVO + IPI vs chemo (HR 0.79, 97.72% CI: 0.65–0.96; P = 0.007); PFS, objective response rates, and duration of response favored NIVO + IPI vs chemo. OS benefit was also observed in pts with PD-L1 < 1% and all randomized pts (Table). Prespecified analyses showed enhanced efficacy with NIVO + IPI relative to NIVO in PD-L1 ≥ 1% and relative to NIVO + chemo in PD-L1 < 1%. Grade 3–4 tx-related adverse event rates in all randomized pts were 33% (N1+1), 19% (N), and 36% (chemo). Conclusions CheckMate 227 met its primary endpoint of significantly improved OS with NIVO + IPI vs chemo in 1L advanced NSCLC with PD-L1 ≥ 1%. OS was also improved with NIVO + IPI in PD-L1 < 1% and in all randomized pts. Safety profile was consistent with previous reports in NSCLC. NIVO + IPI represents a new chemo-free tx option for pts in 1L advanced NSCLC.

Published
2020

20. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer

Author

Hellmann, Matthew D. Paz-Ares, Luis Bernabe Caro, Reyes Zurawski, Bogdan Kim, Sang-We Carcereny Costa, Enric Park, Keunchil Alexandru, Aurelia Lupinacci, Lorena de la Mora Jimenez, Emmanuel Sakai, Hiroshi Albert, Istvan Vergnenegre, Alain Peters, Solange Syrigos, Konstantinos Barlesi, Fabrice Reck, Martin Borghaei, Hossein Brahmer, Julie R. O'Byrne, Kenneth J. Geese, William J. Bhagavatheeswaran, Prabhu Rabindran, Sridhar K. Kasinathan, Ravi S. Nathan, Faith E. Ramalingam, Suresh S.

Abstract

BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC. METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1\% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1\% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1\% or more. RESULTS: Among the patients with a PD-L1 expression level of 1\% or more, the median duration of overall survival was 17.1 months (95\% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95\% CI, 12.7 to 16.7) with chemotherapy (P = 0.007), with 2-year overall survival rates of 40.0\% and 32.8\%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1\%, with a median duration of 17.2 months (95\% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95\% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95\% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95\% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8\% with nivolumab plus ipilimumab and 36.0\% with chemotherapy. CONCLUSIONS: First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826.).

Published
2019

21. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Author

Hellmann, Matthew D., primary, Paz-Ares, Luis, additional, Bernabe Caro, Reyes, additional, Zurawski, Bogdan, additional, Kim, Sang-We, additional, Carcereny Costa, Enric, additional, Park, Keunchil, additional, Alexandru, Aurelia, additional, Lupinacci, Lorena, additional, de la Mora Jimenez, Emmanuel, additional, Sakai, Hiroshi, additional, Albert, Istvan, additional, Vergnenegre, Alain, additional, Peters, Solange, additional, Syrigos, Konstantinos, additional, Barlesi, Fabrice, additional, Reck, Martin, additional, Borghaei, Hossein, additional, Brahmer, Julie R., additional, O’Byrne, Kenneth J., additional, Geese, William J., additional, Bhagavatheeswaran, Prabhu, additional, Rabindran, Sridhar K., additional, Kasinathan, Ravi S., additional, Nathan, Faith E., additional, and Ramalingam, Suresh S., additional

Published
2019
Full Text
View/download PDF

23. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Author

Ready, Neal, primary, Hellmann, Matthew D., additional, Awad, Mark M., additional, Otterson, Gregory A., additional, Gutierrez, Martin, additional, Gainor, Justin F., additional, Borghaei, Hossein, additional, Jolivet, Jacques, additional, Horn, Leora, additional, Mates, Mihaela, additional, Brahmer, Julie, additional, Rabinowitz, Ian, additional, Reddy, Pavan S., additional, Chesney, Jason, additional, Orcutt, James, additional, Spigel, David R., additional, Reck, Martin, additional, O’Byrne, Kenneth John, additional, Paz-Ares, Luis, additional, Hu, Wenhua, additional, Zerba, Kim, additional, Li, Xuemei, additional, Lestini, Brian, additional, Geese, William J., additional, Szustakowski, Joseph D., additional, Green, George, additional, Chang, Han, additional, and Ramalingam, Suresh S., additional

Published
2019
Full Text
View/download PDF

24. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568) : Outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers

Author

Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S., Chesney, Jason, Orcutt, James, Spigel, David R., Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Phd, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J., Szustakowski, Joseph D., Green, George, Chang, Han, Ramalingam, Suresh S., Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S., Chesney, Jason, Orcutt, James, Spigel, David R., Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Phd, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J., Szustakowski, Joseph D., Green, George, Chang, Han, and Ramalingam, Suresh S.

Abstract

PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB). PATIENTS AND METHODS Two hundred eighty-eight patients with previously untreated, recurrent stage IIIB/IV NSCLC received nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks. The primary end point was objective response rate (ORR) in patients with 1% or more and less than 1% tumor PD-L1 expression. Efficacy on the basis of TMB (FoundationOne CDx assay) was a secondary end point. RESULTS Of treated patients with tumor available for testing, 252 patients (88%) of 288 were evaluable for PD-L1 expression and 98 patients (82%) of 120 for TMB. ORR was 30% overall and 41% and 15% in patients with 1% or greater and less than 1% tumor PD-L1 expression, respectively. ORR increased with higher TMB, plateauing at 10 or more mutations/megabase (mut/Mb). Regardless of PD-L1 expression, ORRs were higher in patients with TMB of 10 or more mut/Mb (n = 48: PD-L1, ≥ 1%, 48%; PD-L1, < 1%, 47%) versus TMB of fewer than 10 mut/Mb (n = 50: PD-L1, ≥ 1%, 18%; PD-L1, < 1%, 5%), and progression-free survival was longer in patients with TMB of 10 or more mut/Mb versus TMB of fewer than 10 mut/Mb (median, 7.1 v 2.6 months). Grade 3 to 4 treatment-related adverse events occurred in 29% of patients. CONCLUSION Nivolumab plus low-dose ipilimumab was effective and tolerable as a first-line treatment of advanced/metastatic NSCLC. TMB of 10 or more mut/Mb was associated with improved response and prolonged progression-free survival in both tumor PD-L1 expression 1% or greater and less than 1% subgroups and was thus identified as a potentially relevant cutoff in the assessment of TMB as a biomarker for first-line nivolumab plus ipilimumab.

Published
2019

25. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer

Author

Bristol-Myers Squibb, Ono Pharmaceutical, Hellmann, Matthew D., Paz-Ares, Luis, Bernabé Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, Mora Jiménez, Emmanuel de la, Sakai, Hiroshi, Albert, Istvan, Vergnenegre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie R., O'Byrne, Kenneth J., Geese, William J., Bhagavatheeswaran, Prabhu, Rabindran, Sridhar K., Kasinathan, Ravi S., Nathan, Faith Ellen, Ramalingam, Suresh S., Bristol-Myers Squibb, Ono Pharmaceutical, Hellmann, Matthew D., Paz-Ares, Luis, Bernabé Caro, Reyes, Zurawski, Bogdan, Kim, Sang-We, Carcereny Costa, Enric, Park, Keunchil, Alexandru, Aurelia, Lupinacci, Lorena, Mora Jiménez, Emmanuel de la, Sakai, Hiroshi, Albert, Istvan, Vergnenegre, Alain, Peters, Solange, Syrigos, Konstantinos, Barlesi, Fabrice, Reck, Martin, Borghaei, Hossein, Brahmer, Julie R., O'Byrne, Kenneth J., Geese, William J., Bhagavatheeswaran, Prabhu, Rabindran, Sridhar K., Kasinathan, Ravi S., Nathan, Faith Ellen, and Ramalingam, Suresh S.

Abstract

[Background] In an early-phase study involving patients with advanced non–small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC., [Methods] In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent NSCLC and a PD-L1 expression level of 1% or more in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab alone, or chemotherapy. The patients who had a PD-L1 expression level of less than 1% were randomly assigned in a 1:1:1 ratio to receive nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy alone. All the patients had received no previous chemotherapy. The primary end point reported here was overall survival with nivolumab plus ipilimumab as compared with chemotherapy in patients with a PD-L1 expression level of 1% or more., [Results] Among the patients with a PD-L1 expression level of 1% or more, the median duration of overall survival was 17.1 months (95% confidence interval [CI], 15.0 to 20.1) with nivolumab plus ipilimumab and 14.9 months (95% CI, 12.7 to 16.7) with chemotherapy (P=0.007), with 2-year overall survival rates of 40.0% and 32.8%, respectively. The median duration of response was 23.2 months with nivolumab plus ipilimumab and 6.2 months with chemotherapy. The overall survival benefit was also observed in patients with a PD-L1 expression level of less than 1%, with a median duration of 17.2 months (95% CI, 12.8 to 22.0) with nivolumab plus ipilimumab and 12.2 months (95% CI, 9.2 to 14.3) with chemotherapy. Among all the patients in the trial, the median duration of overall survival was 17.1 months (95% CI, 15.2 to 19.9) with nivolumab plus ipilimumab and 13.9 months (95% CI, 12.2 to 15.1) with chemotherapy. The percentage of patients with grade 3 or 4 treatment-related adverse events in the overall population was 32.8% with nivolumab plus ipilimumab and 36.0% with chemotherapy., [Conclusions] First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expression level. No new safety concerns emerged with longer follow-up. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 227 ClinicalTrials.gov number, NCT02477826. opens in new tab.)

Published
2019

28. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer

Author

CheckMate 026 Investigators, Carbone, David P, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M, Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T Jeroen N, Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M, Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R, Villaruz, Liza C, Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J, Bhagavatheeswaran, Prabhu, Chen, Allen C, Socinski, Mark A, CheckMate 026 Investigators, Lupinacci, L., Martin, C., Pilnik, N., Richardet, M.E., Varela, M.S., Adams, J., Boyer, M., John, T., Moore, M., OByrne, K., Eckmayr, J., Pirker, R., Decoster, L., van Meerbeeck, J., Vansteenkiste, J., Surmont, V., Barrios, C.H., Franke, F.A., Pinto, G., Blais, N., Foley, M.C., Juergens, R., Leighl, N., Morris, D.G., Havel, L., Kolek, V., Krejci, J., Reiterer, P., Roubec, J., Ahvonen, J., Jekunen, A., Maasilta, P., Barlesi, F., Dansen, E., Fraboulet, G., Lena, H., Mennecier, B., Zalcman, G., Frickhofen, N., Kohlhaeufl, M., Reck, M., Repp, R., Steins, M., Wolf, J., Agelaki, S., Syrigos, K., Albert, I., Ostoros, G., Szilasi, M., Cappuzzo, F., Crino, L., De Marinis, F., Gridelli, C., Morabito, A., Roila, F., Atagi, S., Fujita, S., Hida, T., Hirashima, T., Maemondo, M., Minato, K., Nakagawa, K., Nishio, M., Nogami, N., Ohe, Y., Saka, H., Sakai, H., Satouchi, M., Takeda, K., Tanaka, H., Yamamoto, N., Arrieta-Rodriguez, O., De la Mora Jimenez, E., Flores Wilbert, V., Aerts, J., Hiltermann, TJN, Van Den Heuvel, M., Chmielowska, E., Czyzewicz, G., Gabrys, J., Kalinka-Warzocha, E., Pluzanski, A., Kim, H.R., Kim, S.W., Park, K., Cainap, C., Ciuleanu, T.E., Ghizdavescu, D., Blasco, A., Corral Jaime, J., De Castro, J., Felip, E., Paz-Ares, L., Rodriguez Abreu, D., Trigo, J., Kölbeck, K.G., Lindskog, M., Curioni-Fontecedro, A., Mark, M., Peters, S., Chen, Y.M., Karaca, H., Chao, D., Mulatero, C., Summers, Y., Arledge, S., Badin, F., Batus, M., Blumenschein, G., Borghaei, H., Camidge, R., Boyd, T., Brahmer, J., Carbone, D., Cetnar, J., Chachoua, A., Chaft, J., Chen, H., Creelan, B., Gainor, J., Gettinger, S., Gerber, D.E., Horn, L., Kaywin, P., Kessler, R., Langer, C.J., McCracken, J., Nair, S., Oyola, R., Pillai, R., Quddus, F., Rangachari, D., Ready, N., Reynolds, C., Rosenberg, R., Sharma, N., Stinchcombe, T., Villaruz, L., Wakelee, H., Wrangle, J., Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, van Meerbeeck, Jan, et al., and Translational Immunology Groningen (TRIGR)

Subjects
0301 basic medicine, Oncology, Lung Neoplasms, medicine.medical_treatment, THERAPY, B7-H1 Antigen, Lung Neoplasms/chemically induced, 0302 clinical medicine, PACLITAXEL PLUS CARBOPLATIN, Carcinoma, Non-Small-Cell Lung, Clinical endpoint, Carcinoma, Non-Small-Cell Lung/chemically induced, DOCETAXEL, General Medicine, CHEMOTHERAPY, OPEN-LABEL, 3. Good health, Docetaxel, 030220 oncology & carcinogenesis, oncology, TRIAL, Nivolumab, medicine.drug, B7-H1 Antigen/metabolism, medicine.medical_specialty, Antigens, CD274/metabolism, Antineoplastic Agents, Disease-Free Survival, Humans, Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9], Article, 03 medical and health sciences, CISPLATIN, MAINTENANCE BEVACIZUMAB, Internal medicine, medicine, Carcinoma, Lung cancer, neoplasms, Cisplatin, Chemotherapy, business.industry, medicine.disease, PHASE-III, Gemcitabine, respiratory tract diseases, 030104 developmental biology, GEMCITABINE, Human medicine, business
Abstract

BACKGROUNDNivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non-small-cell lung cancer (NSCLC). In an open-label phase 3 trial, we compared first-line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.METHODSWe randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD-L1 tumor-expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum-based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression-free survival, as assessed by means of blinded independent central review, among patients with a PD-L1 expression level of 5% or more.RESULTSAmong the 423 patients with a PD-L1 expression level of 5% or more, the median progression-free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P = 0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment-related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment-related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy.CONCLUSIONSNivolumab was not associated with significantly longer progression-free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD-L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol-Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533.)

Published
2017

29. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Author

Hellmann, Matthew D., primary, Callahan, Margaret K., additional, Awad, Mark M., additional, Calvo, Emiliano, additional, Ascierto, Paolo A., additional, Atmaca, Akin, additional, Rizvi, Naiyer A., additional, Hirsch, Fred R., additional, Selvaggi, Giovanni, additional, Szustakowski, Joseph D., additional, Sasson, Ariella, additional, Golhar, Ryan, additional, Vitazka, Patrik, additional, Chang, Han, additional, Geese, William J., additional, and Antonia, Scott J., additional

Published
2019
Full Text
View/download PDF

31. Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Author

Ramalingam, Suresh S., primary, Hellmann, Matthew D., additional, Awad, Mark M., additional, Borghaei, Hossein, additional, Gainor, Justin, additional, Brahmer, Julie, additional, Spigel, David R., additional, Reck, Martin, additional, O'Byrne, Kenneth J., additional, Paz-Ares, Luis, additional, Zerba, Kim, additional, Li, Xuemei, additional, Geese, William J., additional, Green, George, additional, Lestini, Brian, additional, Szustakowski, Joseph D., additional, Chang, Han, additional, and Ready, Neal, additional

Published
2018
Full Text
View/download PDF

32. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Author

Skoulidis, Ferdinandos, primary, Goldberg, Michael E., additional, Greenawalt, Danielle M., additional, Hellmann, Matthew D., additional, Awad, Mark M., additional, Gainor, Justin F., additional, Schrock, Alexa B., additional, Hartmaier, Ryan J., additional, Trabucco, Sally E., additional, Gay, Laurie, additional, Ali, Siraj M., additional, Elvin, Julia A., additional, Singal, Gaurav, additional, Ross, Jeffrey S., additional, Fabrizio, David, additional, Szabo, Peter M., additional, Chang, Han, additional, Sasson, Ariella, additional, Srinivasan, Sujaya, additional, Kirov, Stefan, additional, Szustakowski, Joseph, additional, Vitazka, Patrik, additional, Edwards, Robin, additional, Bufill, Jose A., additional, Sharma, Neelesh, additional, Ou, Sai-Hong I., additional, Peled, Nir, additional, Spigel, David R., additional, Rizvi, Hira, additional, Aguilar, Elizabeth Jimenez, additional, Carter, Brett W., additional, Erasmus, Jeremy, additional, Halpenny, Darragh F., additional, Plodkowski, Andrew J., additional, Long, Niamh M., additional, Nishino, Mizuki, additional, Denning, Warren L., additional, Galan-Cobo, Ana, additional, Hamdi, Haifa, additional, Hirz, Taghreed, additional, Tong, Pan, additional, Wang, Jing, additional, Rodriguez-Canales, Jaime, additional, Villalobos, Pamela A., additional, Parra, Edwin R., additional, Kalhor, Neda, additional, Sholl, Lynette M., additional, Sauter, Jennifer L., additional, Jungbluth, Achim A., additional, Mino-Kenudson, Mari, additional, Azimi, Roxana, additional, Elamin, Yasir Y., additional, Zhang, Jianjun, additional, Leonardi, Giulia C., additional, Jiang, Fei, additional, Wong, Kwok-Kin, additional, Lee, J. Jack, additional, Papadimitrakopoulou, Vassiliki A., additional, Wistuba, Ignacio I., additional, Miller, Vincent A., additional, Frampton, Garrett M., additional, Wolchok, Jedd D., additional, Shaw, Alice T., additional, Jänne, Pasi A., additional, Stephens, Philip J., additional, Rudin, Charles M., additional, Geese, William J., additional, Albacker, Lee A., additional, and Heymach, John V., additional

Published
2018
Full Text
View/download PDF

33. Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Author

Hellmann, Matthew D., primary, Ciuleanu, Tudor Eliade, additional, Pluzanski, Adam, additional, Lee, Jong Seok, additional, Otterson, Gregory, additional, Audigier-Valette, Clarisse, additional, Minenza, Elisa, additional, Linardou, Helena, additional, Burgers, Sjaak, additional, Salman, Pamela, additional, Borghaei, Hossein, additional, Ramalingam, Suresh S., additional, Brahmer, Julie, additional, Reck, Martin, additional, O'Byrne, Kenneth J., additional, Geese, William J., additional, Green, George, additional, Chang, Han, additional, Szustakowski, Joseph D., additional, Bhagavatheeswaran, Prabhu, additional, Healey, Diane, additional, Fu, Yali, additional, Nathan, Faith, additional, and Paz-Ares, Luis, additional

Published
2018
Full Text
View/download PDF

34. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Author

Gettinger, Scott, primary, Horn, Leora, additional, Jackman, David, additional, Spigel, David, additional, Antonia, Scott, additional, Hellmann, Matthew, additional, Powderly, John, additional, Heist, Rebecca, additional, Sequist, Lecia V., additional, Smith, David C., additional, Leming, Philip, additional, Geese, William J., additional, Yoon, Dennis, additional, Li, Ang, additional, and Brahmer, Julie, additional

Published
2018
Full Text
View/download PDF

35. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Author

Hellmann, Matthew D., primary, Ciuleanu, Tudor-Eliade, additional, Pluzanski, Adam, additional, Lee, Jong Seok, additional, Otterson, Gregory A., additional, Audigier-Valette, Clarisse, additional, Minenza, Elisa, additional, Linardou, Helena, additional, Burgers, Sjaak, additional, Salman, Pamela, additional, Borghaei, Hossein, additional, Ramalingam, Suresh S., additional, Brahmer, Julie, additional, Reck, Martin, additional, O’Byrne, Kenneth J., additional, Geese, William J., additional, Green, George, additional, Chang, Han, additional, Szustakowski, Joseph, additional, Bhagavatheeswaran, Prabhu, additional, Healey, Diane, additional, Fu, Yali, additional, Nathan, Faith, additional, and Paz-Ares, Luis, additional

Published
2018
Full Text
View/download PDF

36. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Author

Hellmann, Matthew D., primary, Nathanson, Tavi, additional, Rizvi, Hira, additional, Creelan, Benjamin C., additional, Sanchez-Vega, Francisco, additional, Ahuja, Arun, additional, Ni, Ai, additional, Novik, Jacki B., additional, Mangarin, Levi M.B., additional, Abu-Akeel, Mohsen, additional, Liu, Cailian, additional, Sauter, Jennifer L., additional, Rekhtman, Natasha, additional, Chang, Eliza, additional, Callahan, Margaret K., additional, Chaft, Jamie E., additional, Voss, Martin H., additional, Tenet, Megan, additional, Li, Xue-Mei, additional, Covello, Kelly, additional, Renninger, Andrea, additional, Vitazka, Patrik, additional, Geese, William J., additional, Borghaei, Hossein, additional, Rudin, Charles M., additional, Antonia, Scott J., additional, Swanton, Charles, additional, Hammerbacher, Jeff, additional, Merghoub, Taha, additional, McGranahan, Nicholas, additional, Snyder, Alexandra, additional, and Wolchok, Jedd D., additional

Published
2018
Full Text
View/download PDF

37. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Author

Hellmann, Matthew D., primary, Callahan, Margaret K., additional, Awad, Mark M., additional, Calvo, Emiliano, additional, Ascierto, Paolo A., additional, Atmaca, Akin, additional, Rizvi, Naiyer A., additional, Hirsch, Fred R., additional, Selvaggi, Giovanni, additional, Szustakowski, Joseph D., additional, Sasson, Ariella, additional, Golhar, Ryan, additional, Vitazka, Patrik, additional, Chang, Han, additional, Geese, William J., additional, and Antonia, Scott J., additional

Published
2018
Full Text
View/download PDF

38. Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Author

Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O'Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph D., Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, Paz-Ares, Luis, Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, Minenza, Elisa, Linardou, Helena, Burgers, Sjaak, Salman, Pamela, Borghaei, Hossein, Ramalingam, Suresh S., Brahmer, Julie, Reck, Martin, O'Byrne, Kenneth J., Geese, William J., Green, George, Chang, Han, Szustakowski, Joseph D., Bhagavatheeswaran, Prabhu, Healey, Diane, Fu, Yali, Nathan, Faith, and Paz-Ares, Luis

Abstract

Nivo + ipi showed promising clinical activity and tolerability as 1L tx for advanced NSCLC in a phase 1 study. Tumor mutation burden (TMB) has emerged as an important biomarker for benefit of immune checkpoint blockade in lung cancer. CheckMate 227 (NCT02477826) is a large, open-label, phase 3 study of 1L nivo + ipi, nivo, or nivo + PT-DC vs PT-DC in advanced NSCLC. A preplanned co-primary endpoint was based on TMB to evaluate progression-free survival (PFS) of nivo + ipi vs PT-DC. This is the first phase 3 study to evaluate TMB as a predictive biomarker for immunotherapy as a co-primary endpoint. We report initial results from Part 1 of the study.

Published
2018

39. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Author

Horn, Leora, primary, Spigel, David R., additional, Vokes, Everett E., additional, Holgado, Esther, additional, Ready, Neal, additional, Steins, Martin, additional, Poddubskaya, Elena, additional, Borghaei, Hossein, additional, Felip, Enriqueta, additional, Paz-Ares, Luis, additional, Pluzanski, Adam, additional, Reckamp, Karen L., additional, Burgio, Marco A., additional, Kohlhäeufl, Martin, additional, Waterhouse, David, additional, Barlesi, Fabrice, additional, Antonia, Scott, additional, Arrieta, Oscar, additional, Fayette, Jérôme, additional, Crinò, Lucio, additional, Rizvi, Naiyer, additional, Reck, Martin, additional, Hellmann, Matthew D., additional, Geese, William J., additional, Li, Ang, additional, Blackwood-Chirchir, Anne, additional, Healey, Diane, additional, Brahmer, Julie, additional, and Eberhardt, Wilfried E.E., additional

Published
2017
Full Text
View/download PDF

40. Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

Author

Brahmer, Julie, primary, Horn, Leora, additional, Jackman, David, additional, Spigel, David, additional, Antonia, Scott, additional, Hellmann, Matthew, additional, Powderly, John, additional, Heist, Rebecca, additional, Sequist, Lecia, additional, Smith, David C., additional, Leming, Philip, additional, Geese, William J., additional, Yoon, Dennis, additional, Li, Ang, additional, and Gettinger, Scott, additional

Published
2017
Full Text
View/download PDF

41. Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026

Author

Peters, Solange, primary, Creelan, Benjamin, additional, Hellmann, Matthew D., additional, Socinski, Mark A., additional, Reck, Martin, additional, Bhagavatheeswaran, Prabhu, additional, Chang, Han, additional, Geese, William J., additional, Paz-Ares, Luis, additional, and Carbone, David P., additional

Published
2017
Full Text
View/download PDF

42. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Author

Carbone, David P., primary, Reck, Martin, additional, Paz-Ares, Luis, additional, Creelan, Benjamin, additional, Horn, Leora, additional, Steins, Martin, additional, Felip, Enriqueta, additional, van den Heuvel, Michel M., additional, Ciuleanu, Tudor-Eliade, additional, Badin, Firas, additional, Ready, Neal, additional, Hiltermann, T. Jeroen N., additional, Nair, Suresh, additional, Juergens, Rosalyn, additional, Peters, Solange, additional, Minenza, Elisa, additional, Wrangle, John M., additional, Rodriguez-Abreu, Delvys, additional, Borghaei, Hossein, additional, Blumenschein, George R., additional, Villaruz, Liza C., additional, Havel, Libor, additional, Krejci, Jana, additional, Corral Jaime, Jesus, additional, Chang, Han, additional, Geese, William J., additional, Bhagavatheeswaran, Prabhu, additional, Chen, Allen C., additional, and Socinski, Mark A., additional

Published
2017
Full Text
View/download PDF

43. Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

Author

Goldman, Jonathan Wade, primary, Antonia, Scott Joseph, additional, Gettinger, Scott N., additional, Borghaei, Hossein, additional, Brahmer, Julie R., additional, Ready, Neal E., additional, Gerber, David E., additional, Chow, Laura Q., additional, Juergens, Rosalyn A., additional, Shepherd, Frances A., additional, Laurie, Scott Andrew, additional, Geese, William J., additional, Li, Ang, additional, Li, Xuemei, additional, and Hellmann, Matthew David, additional

Published
2017
Full Text
View/download PDF

44. Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.

Author

Forde, Patrick M., primary, Chaft, Jamie E., additional, Felip, Enriqueta, additional, Broderick, Stephen, additional, Girard, Nicolas, additional, Awad, Mark M., additional, Kerr, Keith, additional, Blackwood-Chirchir, Anne, additional, Yang, Rong, additional, Geese, William J., additional, and Brahmer, Julie R., additional

Published
2017
Full Text
View/download PDF

45. Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Author

Concha-Benavente, Fernando, primary, Gillison, Maura L., additional, Blumenschein, George R., additional, Harrington, Kevin, additional, Fayette, Jérôme, additional, Colevas, A. Dimitrios, additional, Licitra, Lisa, additional, Kasper, Stefan, additional, Even, Caroline, additional, Worden, Francis P., additional, Saba, Nabil F., additional, Haddad, Robert I., additional, Tahara, Makoto, additional, Hasegawa, Yasuhisa, additional, Yen, Chia-Jui, additional, Lynch, Mark John, additional, Monga, Manish, additional, Geese, William J., additional, Vokes, Everett E., additional, and Ferris, Robert L., additional

Published
2017
Full Text
View/download PDF

46. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Author

Carbone, David P., Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M., Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N., Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M., Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R., Villaruz, Liza C., Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J., Bhagavatheeswaran, Prabhu, Chen, Allen C., Socinski, Mark A., Carbone, David P., Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, Felip, Enriqueta, van den Heuvel, Michel M., Ciuleanu, Tudor-Eliade, Badin, Firas, Ready, Neal, Hiltermann, T. Jeroen N., Nair, Suresh, Juergens, Rosalyn, Peters, Solange, Minenza, Elisa, Wrangle, John M., Rodriguez-Abreu, Delvys, Borghaei, Hossein, Blumenschein, George R., Villaruz, Liza C., Havel, Libor, Krejci, Jana, Corral Jaime, Jesus, Chang, Han, Geese, William J., Bhagavatheeswaran, Prabhu, Chen, Allen C., and Socinski, Mark A.

Published
2017
Full Text
View/download PDF

47. Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Author

Ferris, Robert L., primary, Concha-Benavente, Fernando, additional, Blumenschein, George R., additional, Harrington, Kevin J., additional, Fayette, Jerome, additional, Colevas, A. Dimitrios, additional, Licitra, Lisa F., additional, Kasper, Stefan, additional, Even, Caroline, additional, Gillison, Maura L., additional, Worden, Francis, additional, Saba, Nabil F., additional, Haddad, Robert I., additional, Tahara, Makoto, additional, Hasegawa, Yasuhisa, additional, Yen, Chia-Jui, additional, Lynch, Mark John, additional, Monga, Manish, additional, Geese, William J., additional, and Vokes, Everett E., additional

Published
2017
Full Text
View/download PDF

48. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Author

Ferris, Robert L., primary, Blumenschein, George, additional, Fayette, Jerome, additional, Guigay, Joel, additional, Colevas, A. Dimitrios, additional, Licitra, Lisa, additional, Harrington, Kevin, additional, Kasper, Stefan, additional, Vokes, Everett E., additional, Even, Caroline, additional, Worden, Francis, additional, Saba, Nabil F., additional, Iglesias Docampo, Lara C., additional, Haddad, Robert, additional, Rordorf, Tamara, additional, Kiyota, Naomi, additional, Tahara, Makoto, additional, Monga, Manish, additional, Lynch, Mark, additional, Geese, William J., additional, Kopit, Justin, additional, Shaw, James W., additional, and Gillison, Maura L., additional

Published
2016
Full Text
View/download PDF

49. ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC

Author

Antonia, Scott J., primary, Gettinger, Scott N., additional, Goldman, Jonathan, additional, Brahmer, Julie, additional, Borghaei, Hossein, additional, Chow, Laura Q., additional, Ready, Neal E., additional, Gerber, David E., additional, Juergens, Rosalyn, additional, Shepherd, Frances, additional, Laurie, Scott A., additional, Young, Tina, additional, Geese, William J., additional, Agrawal, Shruti, additional, Li, Xuemei, additional, and Hellmann, Matthew D., additional

Published
2016
Full Text
View/download PDF

50. P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets)

Author

Goldman, Jonathan W., primary, Crino, Lucio, additional, Vokes, Everett E., additional, Holgado, Esther, additional, Reckamp, Karen, additional, Pluzanski, Adam, additional, Spigel, David, additional, Kohlhaeufl, Martin, additional, Garassino, Marina, additional, Chow, Laura Qm, additional, Gettinger, Scott, additional, Gerber, David E., additional, Havel, Libor, additional, Ramalingam, Suresh S., additional, Dy, Grace K., additional, Geese, William J., additional, Li, Ang, additional, Blackwood-Chirchir, Anne, additional, Healey, Diane, additional, Brahmer, Julie, additional, and Lopes, Gilberto, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results